id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7815 R23212 |
Tomson (Levetiracetam), 2015 | Perinatal death (during the first week after delivery from gestational week 24) | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.85 [0.04;16.51] C | 0/296 3/1,763 | 3 | 296 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5932 R15142 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Perinatal death (stillbirth or early neonatal death (0–6 days of age)) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
13.80 [0.26;725.23] C excluded (control group) |
0/13 0/173 | 0 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5913 R14933 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Perinatal death (stillbirth or early neonatal death (0–6 days of age)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
8.11 [0.48;137.00] C excluded (control group) |
0/13 3,543/721,948 | 3,543 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5921 R15029 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Perinatal death (stillbirth or early neonatal death (0–6 days of age)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 6.82 [0.38;122.80] C | 0/13 10/1,800 | 10 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 2.47 [0.31;19.60] | 13 | 309 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam; 2: Levetiracetam) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 5932, 5913